Andhra pradesh forms high power council to strengthen AIDS control measures
Image used is for representational purposes only
VIJAYAWADA: To further strengthen its fight against the HIV-AIDS virus in the state, the
Andhra Pradesh
govt constituted an 18-member high-power council headed by the Chief Secretary. Chief Minister
N Chandrababu Naidu
approved
Health
Minister
Y Satya
Kumar Yadav's proposal in this regard on Wednesday.
The 18-member council will consist of special chief secretaries, principal secretaries, and secretaries of various departments, including health, school education, higher education, women and child development, panchayat raj and rural development, municipal administration and urban development, youth affairs, tourism, agriculture, transport, roads, and buildings.
To ensure the participation of all stakeholders in the fight against AIDS, representatives of affected people like PLHIV and MARP, as well as representatives of Civil Society Organisations (CSOs) and Non-Governmental Organisations (NGOs), will be in the council. In addition, the AP State AIDS Control Society (APSACS) project director will act as the convenor of the council.
The new Andhra Pradesh State Council to oversee control of HIV/AIDS will enable policy decisions and effective implementation of AIDS control programmes through regular monitoring and assessment of the outcomes, resource mobilisation, and better implementation of programmes through inter-departmental coordination and encouraging community participation.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Trade Bitcoin & Ethereum – No Wallet Needed!
IC Markets
Start Now
Undo
The council will convene on a regular basis to oversee the progress of the fight against AIDS. It aims at 100% enrolment of
People Living with HIV
(PLHIV), Most At Risk Population (MARP), and Children Affected By AIDS (CABA), ensuring proper disease preventive and post-disease treatment protocols, and their inclusion in various social protection schemes. The broad-based council is also required to provide proper leadership to the implementation of AIDS control measures in the state through regular review meetings.
Speaking on the occasion, Satya Kumar Yadav, who recommended the constitution of the new council, noted that it will significantly contribute to further strengthening the ongoing efforts to control HIV/AIDS in the state through inter-departmental effort and leveraging of available resources and infrastructure.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Zydus gets USFDA nod for generic IBS-D treatment drug
Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug for the treatment of irritable bowel syndrome with diarrhoea in adults. The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug manufacturing firm said in a regulatory filing. Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea ( IBS-D ) in adults. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Access all TV channels anywhere, anytime Techno Mag Learn More Undo As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US. Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.
Hindustan Times
an hour ago
- Hindustan Times
Talent loss a major threat to addressing global AMR crisis
Antimicrobial resistance (AMR) is turning out to be one of the major health calamities, with two million deaths projected to occur in India alone by 2025 and 10 million globally. While the discovery of penicillin in 1928, revolutionised the field of medicine and saved millions of lives, the industry has witnessed a constant decline in the development of new antibiotics ever since then. The lack of resources and high investments are the widely considered reasons for this gap, but one key aspect that remains largely overlooked is the loss of potent scientific and research talent for more than two decades. In an in-depth research report, Leaving the Lab, AMR Industry Alliance highlights alarming data on this brain drain phenomenon. According to the study, research and development (R&D) workforce is limited with approximately 3,000 AMR researchers currently active in the world, compared to around 46,000 for cancer and 5,000 for HIV/AIDS. Meanwhile, the total number of authors on all AMR publications declined from a high of 3,599 in 1995 to just 1,827 in 2020. Investigators with a focused research interest in AMR too have further declined since the mid-1990s, falling from a peak of 1,300 to less than 700 by 2020. The situation is even more worrisome in the context of India. According to the World Health Organization (WHO), India contributes only 1% to the global antibacterial R&D pipeline, whereas 84% of this research is concentrated in high-income countries, with another 12% in upper-middle-income economies. For a country like India which not only carries one of the world's highest burdens of AMR but also contributes meaningfully to AMR resistance on the global level, the lack of focus on research and innovation severely undermines the efforts to combat this threat. The 2016 UNGA High-Level Meeting on AMR discussed a number of actions, including talent loss to address these challenges globally. However, the industry is still witnessing slow progress on work to contain AMR. This brain drain could further exacerbate the situation if necessary steps aren't taken to tackle the crisis at hand. This current trajectory of AMR research is deeply troubling and stems from a fundamental market failure. Currently most of the private investors and governments prefer directing fund to research in other disease areas, creating a vacuum for companies and SMEs who actively want to amplify work in the field of AMR. And even if some of the biggest players in the market invest in creating new antibiotics, they often don't attract investment. In recent years, AstraZeneca, Novartis, and Johnson & Johnson have all exited or cut back their work on AMR, including closing R&D facilities, selling antimicrobial portfolios, ending AMR development, and letting go of research teams. While SMEs are more agile and innovative in early-stage research and development of antibiotics in comparison to the bigger players, their situation too is marred by lack of funding globally. According to a report by the BEAM Alliance, 54% of the SME members struggle with enough funds to cover even a year's worth of operations and fear bankruptcy. Biopharmaceutical company, Achaogen is a prime example. Even after securing US FDA approval for plazomicin, the company was still forced to declare bankruptcy in April 2019 – after spending nearly a billion dollars and over a decade developing the antibiotic. This phenomenon further exacerbates the broken market for antimicrobials where major pharmaceutical companies are unable to offer long-term careers as they either fear bankruptcy or lack of investments and funding to continue research. On the incentives front, clinicians in antimicrobial and antifungal R&D teams face significant pay gaps when compared to fellowships across all other specialties. In 2022, 44% of infectious disease fellowships went unfilled in the US – more than double the proportion of unfilled fellowships across all specialties. A 2022 Medscape report showed a pay gap of $4,000 between infectious disease doctors and internal medicine doctors across the US, despite the additional years of training and debt required. While India has made commendable strides in public health in the recent years, AMR continues to represent an unprecedented challenge--it can't be resolved by treatment alone. As the most populated country across the globe, India needs to have a strong, sustained investment in scientific human capital to challenge the future risks related to AMR. The government has initiated varied efforts in identifying and filling gaps in knowledge on the development of new antibiotics and alternatives to existing one to combat AMR. For instance, department of biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC's) mission to amplify research in the identification of new bacterial targets; call for proposals under the AMR Interdisciplinary Research (AMRIT) Team Grants, to foster collaborative research in AMR and collaboration with UK-based innovation charity organisation, Nesta, to create a pipeline of innovators who can develop a point–of–care diagnostic test to conserve antibiotics for future generations, are some of the progressive steps in fight against AMR. Additionally, ICMR's flagship initiative Antimicrobial Resistance Surveillance & Research Network (AMRSN) to generate high-quality data on AMR trends across India through 30 tertiary care hospitals and research institutions; funding R&D in areas such as rapid diagnostics, novel antimicrobials with international bodies like WHO, CDC (USA), and the Fleming Fund are other examples of India's efforts. Despite these efforts, challenges do persist in providing the much-needed boost in generating a talented workforce of scientists, researchers and innovators to fight against AMR. One of the major systemic challenges facing loss of scientific talent is due to academia–industry leakages. Despite producing highly skilled microbiologists, pharmacologists, and biotechnologists, LMICs like India struggle to retain researchers in the AMR domain due to inadequate funding, limited career pathways and lack of translational research ecosystems. Additionally, limited interest from the industry to invest in providing hands-on training to the emerging talent further amplifies the challenges. To mitigate these challenges, India Pharma Inc. needs to support adequate funding and pull incentives to support the talent eager to work in the field of AMR. The industry and the government must come together to support antimicrobial stewardship programs while ensuring adequate resources, and robust research infrastructure to retain and nurture talent in the larger ecosystem. Government bodies like BIRAC should further intensify their schemes like Biotechnology Ignition Grant (BIG) or Small Business Innovation Research Initiative (SBIRI) to seed innovation and support long-term product development, and market access in AMR. Given the alacrity of challenge at hand, India must focus towards creating a robust pipeline or sustained funding ecosystem for retaining talent instrumental in pushing new breakthrough in antibiotic discovery. Ensuring that we have a workforce of trained research personnel will be crucial for research funding to go as far as possible and yield the most successful results to tackle AMR. This article is authored by Saransh Chaudhary, president, Global Critical Care, Venus Remedies Ltd and CEO, Venus Medicine Research Centre.
Time of India
2 hours ago
- Time of India
Covid cases rise in India: Active caseloads hit 3,961, 4 more deaths; Kerala, Maharashtra, Delhi worst affected
India's active Covid-19 case count climbed to 3,961 on Monday, June 2—up by 566 since Sunday—as Kerala, Maharashtra, and Delhi continued to report the highest number of infections, according to data from the Ministry of Health and Family Welfare (MoHFW). The country has recorded 32 Covid-related deaths since January 1, including four deaths reported in the past 24 hours. Delhi, Kerala, Maharashtra, and Tamil Nadu each logged one covid-related death. The deceased included a 22-year-old woman in Delhi with a history of post-tuberculosis lung disease and a 44-year-old man in Maharashtra suffering from acute respiratory distress and aortic valve issues. Kerala's latest fatality was reported, though details remain pending. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo Delhi sees sharpest rise again; Tamil Nadu, Karnataka report deaths Delhi reported the sharpest daily increase among major states, adding 47 new active cases and one death. Tamil Nadu, which now has 189 active cases, recorded the death of a 25-year-old man with bronchial asthma and acute tubular injury. Karnataka (253 active cases) also reported a fresh Covid-linked death, while Uttar Pradesh, now with 157 active cases, added two more deaths to its toll. Live Events In total, 16 states and UTs have reported Covid-related fatalities so far this year, though most regions continue to report mild cases and relatively low hospitalisation. Kerala remains worst-hit; Maharashtra, West Bengal follow Kerala continues to bear the heaviest Covid burden, with 1,435 active cases, up from 1,336 the previous day. Maharashtra and Delhi follow with 506 and 483 active cases, respectively. West Bengal has also seen a sharp rise, climbing to 331 active infections. Other states reporting higher caseloads include Karnataka (253), Tamil Nadu (189), Uttar Pradesh (157), Gujarat (338), and Rajasthan (69). Smaller increases were also observed in states like Madhya Pradesh (23), Haryana (28), and Odisha (12). A total of 203 patients were discharged across states in the last 24 hours, bringing the total number of recovered or migrated patients this year to 2,188. Experts: No cause for panic, most cases still mild Despite the surge in numbers, health authorities continue to stress that the overall situation remains under control. Most cases are mild and managed under home isolation. The Indian Council of Medical Research (ICMR) and Health Ministry officials have reiterated that there is no immediate cause for alarm, though they urge the public to stay vigilant. 'We have been closely monitoring the situation. At this moment, overall, we should monitor, be vigilant but there is no cause to worry,' said Dr Rajiv Behl, Director General of ICMR. The increase comes amid the spread of Omicron sub-variants LF.7, XFG, JN.1, and NB.1.8.1, recently detected through genome sequencing in western and southern India. The World Health Organization has labelled these 'Variants Under Monitoring,' indicating they currently pose no global threat. Hospital readiness, vaccination, and masking key to managing spread As a precaution, state health departments—especially in Delhi, Maharashtra, and Kerala—are rechecking hospital preparedness and medical supply chains. Authorities are encouraging mask use in crowded or poorly ventilated areas, especially for the elderly and those with comorbidities. With the virus spreading primarily through new sub-variants that are more contagious but less virulent, experts believe vaccination, timely diagnosis, and responsible behaviour will be crucial in keeping hospitalisation and deaths low. While India's caseload remains a fraction of earlier waves, the recent spike—tenfold in under two weeks—has refocused attention on active monitoring, genome sequencing, and public awareness to prevent another full-blown wave.
